Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 830

1.

Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.

Shorr AF, Sarnes MW, Peeples PJ, Stanford RH, Happe LE, Farrelly E.

Am J Health Syst Pharm. 2007 Nov 15;64(22):2349-55.

PMID:
17989444
2.

Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.

Farias-Eisner R, Horblyuk R, Franklin M, Lunacsek OE, Happe LE.

Curr Med Res Opin. 2009 May;25(5):1081-7. doi: 10.1185/03007990902837117 .

PMID:
19298219
3.

Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.

Shorr AF, Kwong LM, Sarnes M, Happe L, Farrelly E, Mody-Patel N.

Thromb Res. 2007;121(1):17-24. Epub 2007 Apr 20.

PMID:
17449088
4.

Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.

Happe LE, Farrelly EM, Stanford RH, Sarnes MW.

J Thromb Thrombolysis. 2008 Oct;26(2):125-31. Epub 2007 Nov 24.

PMID:
18034323
5.

Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.

Changolkar A, Menditto L, Shah M, Puto K, Farrelly E.

Am J Health Syst Pharm. 2014 Apr 1;71(7):562-9. doi: 10.2146/ajhp120711.

PMID:
24644116
6.
7.

Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.

Bjorvatn A, Kristiansen F.

Am J Cardiovasc Drugs. 2005;5(2):121-30.

PMID:
15725043
8.

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.

van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.

Thromb Haemost. 2009 Apr;101(4):762-9.

PMID:
19350123
9.

Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.

Amin AN, Lin J, Lenhart G, Schulman KL.

Thromb Haemost. 2009 Aug;102(2):321-6. doi: 10.1160/TH09-03-0147.

PMID:
19652883
10.

Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.

Dranitsaris G, Kahn SR, Stumpo C, Paton TW, Martineau J, Smith R, Ginsberg JS; Fondaparinux Canadian Health Economic Study Investigators.

Am J Cardiovasc Drugs. 2004;4(5):325-33.

PMID:
15449974
11.

Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.

Tran AH, Lee G.

Ann Pharmacother. 2003 Nov;37(11):1632-43. Review.

PMID:
14565815
12.

Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.

Capri S, Ageno W, Imberti D, Palareti G, Piovella F, Scannapieco G, Moia M.

Intern Emerg Med. 2010 Feb;5(1):33-40. doi: 10.1007/s11739-009-0324-6. Epub 2009 Nov 5.

PMID:
19890611
13.

Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.

Deitelzweig SB, Becker R, Lin J, Benner J.

Thromb Haemost. 2008 Nov;100(5):810-20.

PMID:
18989525
14.

Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.

Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS.

Clin Ther. 2007 Nov;29(11):2395-405. Review.

PMID:
18158080
15.

Comparative effectiveness of dalteparin and enoxaparin in a hospital setting.

Carson W, Schilling B, Simons WR, Parks C, Choe Y, Faria C, Powers A.

J Pharm Pract. 2012 Apr;25(2):180-9. doi: 10.1177/0897190011418514. Epub 2011 Oct 10.

PMID:
21987527
16.

Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.

Wade WE, Spruill WJ.

Am J Ther. 2008 Nov-Dec;15(6):512-5. doi: 10.1097/MJT.0b013e3181727aa0.

PMID:
19127133
17.
18.

The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.

Gordois A, Posnett J, Borris L, Bossuyt P, Jönsson B, Levy E, de Pouvourville G.

J Thromb Haemost. 2003 Oct;1(10):2167-74.

19.

Postdischarge oral versus injectable anticoagulation following major orthopedic surgery.

Shorr AF, Nutescu EA, Farrelly E, Horblyuk R, Happe LE, Franklin M.

Ann Pharmacother. 2008 Sep;42(9):1222-8. doi: 10.1345/aph.1L113. Epub 2008 Jul 29.

PMID:
18664606
20.

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.

Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW; Matisse Investigators.

J Thromb Haemost. 2007 Jun;5(6):1191-4.

Supplemental Content

Support Center